Senju Pharmaceutical Co. v. Lupin Limited, No. 13-1630 (Fed. Cir. Mar. 20, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This is a patent case brought under the Hatch- Waxman Act , Pub. L. No. 98 -417, 98 Stat. 1585 (“the Act”), on appeal from the United States District Court for the District of Delaware. Pursuant to the Act, p laintiffs- appellants Senju Pharmaceutical Co., Ltd., Kyorin Pha r- maceutical Co., Ltd., and Allergan, Inc. (collectively “Senju”) sued defendants -appellees Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively “Lupin”) and Hi- Tech Pharmacal Co., Inc. (“Hi -Tech”) for infringement of asserted claims 6 and 12- 16 of reexamined U.S.